Skip to content

Clinical observation of cervical lymphatic/nodal-venous anastomosis in the treatment of AD-derived cognitive dysfunction

Clinical observation of cervical lymphatic/nodal-venous anastomosis in the treatment of AD-derived cognitive dysfunction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104671
Enrollment
Unknown
Registered
2025-06-20
Start date
2025-01-05
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer`s disease

Interventions

Experimental group:Cervical lymphatic/nodal-venous anastomosis treatment

Sponsors

Affiliated Hospital of Zunyi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The patient or guardian signs the informed consent form; 2. Age 50~85 years old (>= 50 years old, = grade 1, <= grade 3).

Exclusion criteria

Exclusion criteria: 1. Presence of contraindications to MRI or PET scanning; 2. Presence of contraindications to lumbar puncture; 3. Severe cardiac disease or unstable hemodynamic status; 4. Severe pulmonary disease, including severe obstructive, restrictive, or mixed ventilatory dysfunction, or Acute inflammation within 3 months; 5. Hepatic insufficiency, AST or ALT > 3 times the normal high line; 6. Renal insufficiency, GFR = 180mmHg or diastolic blood pressure >= 110mmHg; 13. Diseases require systemic hormones; 14. Drug addiction (including sperm, narcotics and alcohol addiction); 15. Serious infectious diseases, including HIV-positive, severe infection, etc. 16. Severe mental illness or potential risk of suicide; 17. Within 3 years after radical resection of malignant tumors; 18. Participation in other interventional clinical trials within the past three months; 19. The physician judged that the compliance was poor, unable to complete or unwilling to cooperate with the regular follow-up after surgery; 20. Other conditions that the physician considers unsuitable for this clinical trial.

Design outcomes

Primary

MeasureTime frame
Mini-Mental State Examination;Neuropsychiatric Inventory;activities of daily living;montreal cognitive assessment;Clinical Dementia Rating Scale;Apathy Evaluation Scale;

Secondary

MeasureTime frame
Neck ultrasound;MRI scan;Plasma Aß-42, Aß-40, Aß-42/Aß-40 concentration levels;Cerebrospinal fluid P-tau181 concentration level;Plasma P-tau181 concentration levels;Cerebrospinal fluid Aß-42, Aß-40, Aß-42/Aß-40 concentration levels;

Countries

China

Contacts

Public ContactDeng Chengliang

Affiliated Hospital of Zunyi Medical University

260851047@qq.com+86 15085115296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026